We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




IVF Hormonal Treatment Causes Negligible Cancer Risk

By HospiMedica International staff writers
Posted on 13 Jul 2014
Print article
A new long-term study of women who used ovary-stimulating hormones for in vitro fertilization (IVF) treatment found no widespread evidence of a higher cancer risk.

Researchers at the University of Illinois in Chicago (UIC; USA) and the US National Cancer Institute (NCI; Bethesda, MD, USA) conducted a retrospective investigation involving 12,193 women treated for infertility between 1965 and 1988 at five US sites. Follow-up lasted until 2010, with evaluation based on questionnaire and linkage to US death and cancer registries. Over the 30 years of follow-up, 749 breast, 119 endometrial (uterine), and 85 ovarian cancers were identified in the 9,892 subjects who were successfully followed.

The results showed that use of clomiphene, which included approximately 40% of the cohort, was not associated with any increased breast cancer risk, except when subjects had used the drug in 12 or more treatment cycles; in those cases clomiphene use was associated with a hazard ratio of invasive breast cancer of 1.69, but was not significantly associated with either endometrial or ovarian cancers, even when multiple exposure cycles were involved.

Only 10% of the cohort had been treated with human menopausal gonadotrophins (hMG) and follicle stimulating hormone (FSH), usually in combination with clomiphene, and there was no association with cancer risk identified, except in those who remained childless. The study was presented at the annual conference of the European Society of Human Reproduction and Embryology (ESHRE), held during June 2014 in Munich (Germany).

“The findings do not support a strong relationship between the use of fertility drugs and breast, uterine, and ovarian cancers. Continued monitoring is needed to see whether any of the newer drugs present any danger,” said study presenter and coauthor Humberto Scoccia, MD, of UCI. “Most of the women who enrolled in the study are still relatively young and these types of cancers tend to show up in later years. It is also likely that the proportion of patients using gonadotrophins for ovarian stimulation, particularly in IVF, increased substantially after the mid-1980s.”

Fertility drugs are known to increase levels of the principal female hormones estradiol and progesterone, both of which have been implicated in the pathogenesis of breast, ovarian, and uterine cancers.

Related Links:

University of Illinois in Chicago
US National Cancer Institute


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Neonatal Transport Ventilator
Babylite

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.